Santen Pharmaceutical Co., Ltd.
4536
Rang in aandelen
#4330
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
Aandeelprijs
$11.35
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$3.65B
Verandering (1 dag)
1.55%
Verandering (1 jaar)
-0.91%
Land
JP
Handel Santen Pharmaceutical Co., Ltd. (4536)
Categorie
Healthcare
Marktkapitalisatie van Santen Pharmaceutical Co., Ltd.(4536)
Marktkapitalisatie: $3.65B
Vanaf October 2026 heeft Santen Pharmaceutical Co., Ltd. een marktkapitalisatie van $3.65B. Dit maakt Santen Pharmaceutical Co., Ltd. volgens onze gegevens het 4330th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Santen Pharmaceutical Co., Ltd. van 2010 tot 2026
4536 vergeleken met de top 5 populairste stocks
